Literature DB >> 26781859

SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.

Kaichun Li1, Mingzhen Ying1, Dan Feng1, Yan Chen2, Jingwen Wang3, Yajie Wang1.   

Abstract

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer, which is characterized by the negative form of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). TNBC accounts for ~15% of all breast cancer forms, and often leads to high mortality and poor prognosis. Structural maintenance of chromosome 1 (SMC1) is a subunit of the cohesion protein complex. Brachyury is a protein that is encoded by the T gene in humans, which is a transcription factor within the T-box complex of genes. Epithelial-mesenchymal transition (EMT) is a ubiquitous process in the body, and in particular, induces metastasis and the proliferation of cancer cells. In the present study, we found that SMC1 expression in TNBC tissues exceeded its expression in adjacent non-tumor tissues. Similarly, the expression of SMC1 in TNBC cell lines (hs578T and HCC1937) was found to be higher than in MCF10a and MCF7 cells. Subsequently, SMC1 was overexpressed and silenced in hs578T and HCC1937 cells through plasmid and siRNA transfection, respectively. The results showed that the high expression of SMC1 often promoted EMT, accompanied by the enhanced expression of Brachyury. Besides, upregulated expression of Brachyury through plasmid transfection also significantly improved the level of EMT, which further indicated that SMC1 increased EMT in TNBC through the induction of Brachyury expression. Taken together, these results contributed to a better understanding of the pathogenesis of TNBC, which also provided an experimental basis for the prevention, diagnosis and treatment of TNBC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26781859     DOI: 10.3892/or.2016.4564

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Authors:  Sagar R Shah; Justin M David; Nathaniel D Tippens; Ahmed Mohyeldin; Juan C Martinez-Gutierrez; Sara Ganaha; Paula Schiapparelli; Duane H Hamilton; Claudia Palena; Andre Levchenko; Alfredo Quiñones-Hinojosa
Journal:  Cell Rep       Date:  2017-10-10       Impact factor: 9.423

Review 2.  Structural Maintenance of Chromosomes protein 1: Role in Genome Stability and Tumorigenesis.

Authors:  Fei Yi; Zhuo Wang; Jingwei Liu; Ying Zhang; Zhijun Wang; Hongde Xu; Xiaoman Li; Ning Bai; Liu Cao; Xiaoyu Song
Journal:  Int J Biol Sci       Date:  2017-09-03       Impact factor: 6.580

3.  Machine learning based tissue analysis reveals Brachyury has a diagnosis value in breast cancer.

Authors:  Kaichun Li; Qiaoyun Wang; Yanyan Lu; Xiaorong Pan; Long Liu; Shiyu Cheng; Bingxiang Wu; Zongchang Song; Wei Gao
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

4.  Multiple malignant tumors in a patient with familial chordoma, a case report.

Authors:  Nuttavut Sumransub; Paari Murugan; Shelly Marette; Denis R Clohisy; Keith M Skubitz
Journal:  BMC Med Genomics       Date:  2021-08-31       Impact factor: 3.063

5.  Comprehensive Analysis of SMC Gene Family Prognostic Value and Immune Infiltration in Patients With Pancreatic Adenocarcinoma.

Authors:  Hui Nie; Yanhao Wu; Chunlin Ou; Xiaoyun He
Journal:  Front Med (Lausanne)       Date:  2022-03-15

6.  The deacetylation-phosphorylation regulation of SIRT2-SMC1A axis as a mechanism of antimitotic catastrophe in early tumorigenesis.

Authors:  Fei Yi; Ying Zhang; Zhijun Wang; Zhuo Wang; Ziwei Li; Tingting Zhou; Hongde Xu; Jingwei Liu; Bo Jiang; Xiaoman Li; Liang Wang; Ning Bai; Qiqiang Guo; Yi Guan; Yanling Feng; Zhiyong Mao; Guangjian Fan; Shengping Zhang; Chuangui Wang; Longyue Cao; Brian P O'Rourke; Yang Wang; Yanmei Wu; Boquan Wu; Shilong You; Naijin Zhang; Junlin Guan; Xiaoyu Song; Yingxian Sun; Shi Wei; Liu Cao
Journal:  Sci Adv       Date:  2021-02-24       Impact factor: 14.957

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.